Clinical Trials Using Glucocorticoid Receptor Antagonist CORT125134
Clinical trials are research studies that involve people. The clinical trials on this list are studying Glucocorticoid Receptor Antagonist CORT125134. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors
The purpose of this study is to assess the safety of the combination of CORT125134, a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in patients with solid tumors and to determine the preliminary efficacy of the combination of CORT125134 and nab-paclitaxel. The structure for the study is a single arm, non-randomized, open- label, multicenter trial with no control group.
Location: 2 locations
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.
Location: 2 locations
Enzalutamide and Relacorilant in Treating Patients with Metastatic Castration Resistant Prostate Cancer
This phase I trial studies the best dose and side effects of enzalutamide and relacorilant in treating patients with castration resistant prostate cancer that has spread to other places in the body. Drugs, such as enzalutamide and relacorilant, may lessen the amount of androgens made by the body. It is not yet known whether enzalutamide and relacorilant may work better in treating patients with castration resistant prostate cancer.
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois